Catalog No.
DHB86901
Host species
Homo sapiens
Species reactivity
Human
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Concentration
1 mg/ml
Purity
>95% by SDS-PAGE.
Clonality
Monoclonal
Isotype
IgG1-kappa
Applications
Research Grade Biosimilar
Target
HER1, Receptor tyrosine-protein kinase erbB-1, Proto-oncogene c-ErbB-1, Epidermal growth factor receptor, EGFR, ERBB1, ERBB
Purification
Protein A or G purified from cell culture supernatant.
Endotoxin level
Please contact with the lab for this information.
Expression system
XtenCHO
Accession
P00533
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.
Alternative Names
11F8, IMC-11F8, LY3012211, CAS: 906805-06-9
Note
For research use only. Not suitable for clinical or therapeutic use.
Necitumumab, PMID: 31643800
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial, PMID: 26045340
Necitumumab, PMID: 29999841
Necitumumab for the treatment of advanced non-small-cell lung cancer, PMID: 30501503
Necitumumab in the treatment of non-small-cell lung cancer: clinical controversies, PMID: 30075697
Necitumumab: First Global Approval, PMID: 26729188
Necitumumab: a new option for first-line treatment of squamous cell lung cancer, PMID: 30025476
Necitumumab, a fully human IgG1 mAb directed against the EGFR for the potential treatment of cancer, PMID: 21154125
Necitumumab for non-small cell lung cancer, PMID: 26051700
Necitumumab for the treatment of squamous cell non-small cell lung cancer, PMID: 27913776
Spotlight on necitumumab in the treatment of non-small-cell lung carcinoma, PMID: 28293124
Clinical potential of necitumumab in non-small cell lung carcinoma, PMID: 27621656
Necitumumab in Metastatic Squamous Cell Lung Cancer: Establishing a Value-Based Cost, PMID: 26313558
Necitumumab in the treatment of advanced non-small cell lung cancer: translation from preclinical to clinical development, PMID: 21679088
Population Pharmacokinetics of Necitumumab in Cancer Patients, PMID: 27696220
Necitumumab plus platinum-based chemotherapy versus chemotherapy alone as first-line treatment for stage IV non-small cell lung cancer: a meta-analysis based on randomized controlled trials, PMID: 32954751
Will Necitumumab Be Cost-Effective?, PMID: 26380602
Efficacy and safety of necitumumab and pembrolizumab combination therapy in patients with Stage IV non-small cell lung cancer, PMID: 32114283
Molecular Basis for Necitumumab Inhibition of EGFR Variants Associated with Acquired Cetuximab Resistance, PMID: 29158469
The Effect of Necitumumab in Combination with Gemcitabine plus Cisplatin on Tolerability and on Quality of Life: Results from the Phase 3 SQUIRE Trial, PMID: 26980471
Effects of adding necitumumab to first-line chemotherapy in patients with stage IV non-small-cell lung cancer: Meta-analysis, PMID: 31822198
A phase 1b study of necitumumab in combination with abemaciclib in patients with stage IV non-small cell lung cancer, PMID: 31586771
A phase II study of nab-paclitaxel and carboplatin chemotherapy plus necitumumab in the first-line treatment of patients with stage IV squamous non-small cell lung cancer, PMID: 31445354
Efficacy and Safety of Necitumumab Continuation Therapy in the Phase III SQUIRE Study of Patients With Stage IV Squamous Non-Small-Cell Lung Cancer, PMID: 29158123
Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study, PMID: 25701171
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan, PMID: 30797492
Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer, PMID: 29175116
Necitumumab in squamous non-small-cell lung cancer: how to move forward?, PMID: 27329250
Evaluation of the effect of necitumumab on the corrected QT interval in patients with advanced solid tumors, PMID: 27312733
Necitumumab plus Gemcitabine and Cisplatin as First-Line Therapy in Patients with Stage IV EGFR- Expressing Squamous Non-Small-Cell Lung Cancer: German Subgroup Data from an Open-Label, Randomized Controlled Phase 3 Study (SQUIRE), PMID: 27614872
A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies, PMID: 20197484
Exposure-Response Analysis of Necitumumab Efficacy in Squamous Non-Small Cell Lung Cancer Patients, PMID: 28569042
Drug Monographs: Ixazomib and Necitumumab, PMID: 27303088
Necitumumab for patients with non-squamous NSCLC: uninspiring results, PMID: 25701169
Necitumumab for the treatment of stage IV metastatic squamous non-small-cell lung cancer, PMID: 25797462
Cangrelor, PMID: 27729681
EGFR targeting for cancer therapy: Pharmacology and immunoconjugates with drugs and nanoparticles, PMID: 33188892
EGFR Gene Copy Number by FISH May Predict Outcome of Necitumumab in Squamous Lung Carcinomas: Analysis from the SQUIRE Study, PMID: 29158193
An Open-Label, Randomized, Controlled Phase II Study of Paclitaxel-Carboplatin Chemotherapy With Necitumumab Versus Paclitaxel-Carboplatin Alone in First-Line Treatment of Patients With Stage IV Squamous Non-Small-Cell Lung Cancer, PMID: 28365238
Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer, PMID: 27207107
Corrigendum to "Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan" [Lung Cancer, 129 (March) (2019) 55-62], PMID: 31014853
Necitumumab: a new therapeutic option for squamous cell lung cancer?, PMID: 25806327
Portrazza (Necitumumab), an IgG1 Monoclonal Antibody, FDA Approved for Advanced Squamous Non-Small-Cell Lung Cancer, PMID: 27668058
Necitumumab for first-line treatment of advanced, squamous, non-small-cell lung cancer: a relevant step forward?, PMID: 26958500
Efficacy and Safety of First-Line Necitumumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in East Asian Patients with Stage IV Squamous Non-small Cell Lung Cancer: A Subgroup Analysis of the Phase 3, Open-Label, Randomized SQUIRE Study, PMID: 28111429
NICE guidance on necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer, PMID: 27692477
Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer, PMID: 26766738
Venous thromboembolism with EGFR monoclonal antibody necitumumab in stage IV non-small cell lung cancer: A retrospective cohort analysis, PMID: 29787943
Phase I study of the second-generation, recombinant, human EGFR antibody necitumumab in Japanese patients with advanced solid tumors, PMID: 27628194
The Budget Impact of Including Necitumumab on the Formulary for First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer: U.S. Commercial Payer and Medicare Perspectives, PMID: 29799326
For research use only. Not for human or drug use.
